Stock Track | Recursion Pharmaceuticals Plummets 5.90% as Analyst Cites Concerns Over AI Drug Discovery and High Cash Burn

Stock Track11-21 00:22

Recursion Pharmaceuticals, Inc. (RXRX) saw its stock plummet by 5.90% in intraday trading on Wednesday, as a bearish analyst report raised concerns about the company's AI-driven drug discovery approach and its financial stability.

According to the analyst's report, Recursion has consistently been rated as a "Hold" due to skepticism surrounding its AI-powered drug discovery model and its financial instability. The company has reported significant losses and a high cash burn rate, putting pressure on it to secure new funding or revenue streams.

The recently announced merger with Exscientia brings additional cash but also increased R&D costs, making it likely that the combined company will need to raise more funds soon. Furthermore, the analyst stated that Recursion's pipeline lacks compelling catalysts in the near term, and revenues from its drug candidates in the next five years seem unlikely.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1149413635?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-21 00:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1149413635","market":"us","top_or_hot":-1,"title":"Stock Track | Recursion Pharmaceuticals Plummets 5.90% as Analyst Cites Concerns Over AI Drug Discovery and High Cash Burn","media":"Stock Track","content":"<p>Recursion Pharmaceuticals, Inc. (RXRX) saw its stock plummet by 5.90% in intraday trading on Wednesday, as a bearish analyst report raised concerns about the company's AI-driven drug discovery approach and its financial stability.</p>\n\n<p>According to the analyst's report, Recursion has consistently been rated as a \"Hold\" due to skepticism surrounding its AI-powered drug discovery model and its financial instability. The company has reported significant losses and a high cash burn rate, putting pressure on it to secure new funding or revenue streams.</p>\n\n<p>The recently announced merger with Exscientia brings additional cash but also increased R&D costs, making it likely that the combined company will need to raise more funds soon. Furthermore, the analyst stated that Recursion's pipeline lacks compelling catalysts in the near term, and revenues from its drug candidates in the next five years seem unlikely.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Recursion Pharmaceuticals Plummets 5.90% as Analyst Cites Concerns Over AI Drug Discovery and High Cash Burn</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Recursion Pharmaceuticals Plummets 5.90% as Analyst Cites Concerns Over AI Drug Discovery and High Cash Burn\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-21 00:22 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Recursion Pharmaceuticals, Inc. (RXRX) saw its stock plummet by 5.90% in intraday trading on Wednesday, as a bearish analyst report raised concerns about the company's AI-driven drug discovery ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RXRX","symbol_name":"Recursion Pharmaceuticals, Inc.","start_time":0,"source_url":"","article_id":"1149413635","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1149413635","pubTimestamp":1732119757,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Recursion Pharmaceuticals, Inc.  saw its stock plummet by 5.90% in intraday trading on Wednesday, as a bearish analyst report raised concerns about the company's AI-driven drug discovery approach and its financial stability.According to the analyst's report, Recursion has consistently been rated as a \"Hold\" due to skepticism surrounding its AI-powered drug discovery model and its financial instability. The company has reported significant losses and a high cash burn rate, putting pressure on it ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RXRX":"Recursion Pharmaceuticals, Inc."},"translate_title":"分析师表示对人工智能药物发现和高现金消耗的担忧，Recursion Pharmaceuticals股价暴跌5.90%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RXRX":1},"content_text":"Recursion Pharmaceuticals, Inc. (RXRX) saw its stock plummet by 5.90% in intraday trading on Wednesday, as a bearish analyst report raised concerns about the company's AI-driven drug discovery approach and its financial stability.\nAccording to the analyst's report, Recursion has consistently been rated as a \"Hold\" due to skepticism surrounding its AI-powered drug discovery model and its financial instability. The company has reported significant losses and a high cash burn rate, putting pressure on it to secure new funding or revenue streams.\nThe recently announced merger with Exscientia brings additional cash but also increased R&D costs, making it likely that the combined company will need to raise more funds soon. Furthermore, the analyst stated that Recursion's pipeline lacks compelling catalysts in the near term, and revenues from its drug candidates in the next five years seem unlikely.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1149413635"}